These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16848778)

  • 41. Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction.
    Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Brenner T; Laub O; Souroujon MC
    Ann N Y Acad Sci; 2008; 1132():244-8. PubMed ID: 18567875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
    MacMillan HF; Lee T; Issekutz AC
    Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of the Fc function in human immunoglobulins for intravenous administration. Multicenter study of the section 'Blood plasma Constituents' of the German Association for Transfusion Medicine and Immunohematology (DGTI).
    Kotitschke R
    Infusionsther Transfusionsmed; 1993 Jun; 20(3):93-5. PubMed ID: 8364334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A full complement of receptors in immune complex diseases.
    Ravetch JV
    J Clin Invest; 2002 Dec; 110(12):1759-61. PubMed ID: 12488423
    [No Abstract]   [Full Text] [Related]  

  • 45. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
    Crow AR; Song S; Siragam V; Lazarus AH
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection.
    Dimaano EM; Saito M; Honda S; Miranda EA; Alonzo MT; Valerio MD; Mapua CA; Inoue S; Kumaori A; Matias R; Natividad FF; Oishi K
    Am J Trop Med Hyg; 2007 Dec; 77(6):1135-8. PubMed ID: 18165536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Intravenous immunoglobulin: another therapeutic application].
    de Gracia R; Jiménez C; Gil F; Escuín F; Castell J; Sanz A
    Nefrologia; 2007; 27(2):214-6. PubMed ID: 17564568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-cell interactions: Fc receptors.
    Kinet JP
    Cell; 1989 May; 57(3):351-4. PubMed ID: 2655922
    [No Abstract]   [Full Text] [Related]  

  • 49. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin.
    Park-Min KH; Serbina NV; Yang W; Ma X; Krystal G; Neel BG; Nutt SL; Hu X; Ivashkiv LB
    Immunity; 2007 Jan; 26(1):67-78. PubMed ID: 17239631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous immunoglobulin in MS: promise or failure?
    Fazekas F; Strasser-Fuchs S; Hommes OR
    J Neurol Sci; 2007 Aug; 259(1-2):61-6. PubMed ID: 17449063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation.
    Kastl SP; Speidl WS; Kaun C; Rega G; Assadian A; Weiss TW; Valent P; Hagmueller GW; Maurer G; Huber K; Wojta J
    J Thromb Haemost; 2006 Aug; 4(8):1790-7. PubMed ID: 16879222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics.
    Sapan CV; Reisner HM; Lundblad RL
    Vox Sang; 2007 Apr; 92(3):197-205. PubMed ID: 17348868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?
    Corbí AL; Sánchez-Ramón S; Domínguez-Soto A
    Immunotherapy; 2016 May; 8(5):601-12. PubMed ID: 27140412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fc-receptors as regulators of immunity.
    Nimmerjahn F; Ravetch JV
    Adv Immunol; 2007; 96():179-204. PubMed ID: 17981207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?
    Crow AR; Lazarus AH
    Transfus Med Rev; 2008 Apr; 22(2):103-16. PubMed ID: 18353251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intravenous immunoglobulin treatment in autoimmune diseases].
    Danieli MG; Calcabrini L; Marchetti A; Calabrese V; Pettinari L; Massaccesi C; Gabrielli A; Danieli G
    Recenti Prog Med; 2007 Jun; 98(6):322-6. PubMed ID: 17580523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction.
    Fuchs S; Feferman T; Zhu KY; Meidler R; Margalit R; Wang N; Laub O; Souroujon MC
    Ann N Y Acad Sci; 2007 Sep; 1110():550-8. PubMed ID: 17911471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A microassay for measurement of Fc function of human immunoglobulin preparations by using tetanus toxoid as antigen.
    Vrdoljak A; Trescec A; Benko B; Simic M
    Biologicals; 2004 Jun; 32(2):78-83. PubMed ID: 15454185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors.
    Bertolotti-Ciarlet A; Wang W; Lownes R; Pristatsky P; Fang Y; McKelvey T; Li Y; Li Y; Drummond J; Prueksaritanont T; Vlasak J
    Mol Immunol; 2009 May; 46(8-9):1878-82. PubMed ID: 19269032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.